PL3452485T3 - Inhibitory arginazy oraz ich zastosowania terapeutyczne - Google Patents

Inhibitory arginazy oraz ich zastosowania terapeutyczne

Info

Publication number
PL3452485T3
PL3452485T3 PL17721137T PL17721137T PL3452485T3 PL 3452485 T3 PL3452485 T3 PL 3452485T3 PL 17721137 T PL17721137 T PL 17721137T PL 17721137 T PL17721137 T PL 17721137T PL 3452485 T3 PL3452485 T3 PL 3452485T3
Authority
PL
Poland
Prior art keywords
therapeutic applications
arginase inhibitors
arginase
inhibitors
therapeutic
Prior art date
Application number
PL17721137T
Other languages
English (en)
Inventor
Roman BŁASZCZYK
Julita NOWICKA
Bartłomiej Borek
Joanna BRZEZIŃSKA
Anna GZIK
Marek DZIĘGIELEWSKI
Adam Golebiowski
Karol JĘDRZEJCZAK
Krzysztof MATYSZEWSKI
Jacek OLCZAK
Original Assignee
Oncoarendi Therapeutics S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics S.A. filed Critical Oncoarendi Therapeutics S.A.
Publication of PL3452485T3 publication Critical patent/PL3452485T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17721137T 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne PL3452485T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10
PCT/EP2017/060413 WO2017191130A2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
EP17721137.2A EP3452485B1 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
PL3452485T3 true PL3452485T3 (pl) 2021-04-19

Family

ID=60190450

Family Applications (2)

Application Number Title Priority Date Filing Date
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL17721137T PL3452485T3 (pl) 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Country Status (24)

Country Link
US (3) US10391077B2 (pl)
EP (1) EP3452485B1 (pl)
JP (1) JP6971477B2 (pl)
KR (1) KR102374788B1 (pl)
CN (1) CN109415387B (pl)
AU (1) AU2017259887B2 (pl)
BR (1) BR112018072545B1 (pl)
CA (1) CA3022482C (pl)
CL (1) CL2018003132A1 (pl)
CO (1) CO2018013077A2 (pl)
DK (1) DK3452485T3 (pl)
ES (1) ES2834065T3 (pl)
HR (1) HRP20201821T1 (pl)
HU (1) HUE052468T2 (pl)
IL (1) IL262387B (pl)
LT (1) LT3452485T (pl)
MX (1) MX378806B (pl)
PE (1) PE20181924A1 (pl)
PH (1) PH12018501976A1 (pl)
PL (2) PL417066A1 (pl)
SA (1) SA518400356B1 (pl)
SG (1) SG11201807974QA (pl)
SI (1) SI3452485T1 (pl)
WO (1) WO2017191130A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
KR102656571B1 (ko) * 2018-03-05 2024-04-11 아르커스 바이오사이언시즈 인코포레이티드 아르기나아제 억제제
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3774843B1 (en) * 2018-03-29 2022-05-25 Molecure SA Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
ES3034676T3 (en) 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021096542A1 (en) 2019-11-12 2021-05-20 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20240336635A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]-cyclohexane-1-carboxylic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP2083812B1 (en) 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
HRP20191433T1 (hr) 2009-01-26 2019-11-15 Univ Pennsylvania Inhibitori arginaze i metode primjene
US9040703B2 (en) 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2013249790B2 (en) * 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
AU2019211067A1 (en) 2018-01-28 2020-08-13 Universite De Geneve Arginase suppression for cancer treatment

Also Published As

Publication number Publication date
DK3452485T3 (da) 2020-11-09
CN109415387A (zh) 2019-03-01
WO2017191130A2 (en) 2017-11-09
US12053451B2 (en) 2024-08-06
US20170319536A1 (en) 2017-11-09
MX2018013387A (es) 2019-02-28
HRP20201821T1 (hr) 2021-04-16
KR20190015250A (ko) 2019-02-13
US20210260019A1 (en) 2021-08-26
AU2017259887B2 (en) 2022-03-17
ES2834065T3 (es) 2021-06-16
US10391077B2 (en) 2019-08-27
SI3452485T1 (sl) 2021-01-29
CN109415387B (zh) 2021-08-27
LT3452485T (lt) 2020-12-28
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
BR112018072545A2 (pt) 2019-06-25
CL2018003132A1 (es) 2019-02-22
WO2017191130A3 (en) 2017-12-14
PE20181924A1 (es) 2018-12-11
NZ746211A (en) 2024-12-20
EP3452485A2 (en) 2019-03-13
HUE052468T2 (hu) 2021-04-28
PL417066A1 (pl) 2017-11-06
AU2017259887A1 (en) 2018-09-27
PH12018501976A1 (en) 2019-07-01
CA3022482A1 (en) 2017-11-09
JP6971477B2 (ja) 2021-11-24
SG11201807974QA (en) 2018-10-30
IL262387B (en) 2021-10-31
JP2019518726A (ja) 2019-07-04
CO2018013077A2 (es) 2019-04-30
MX378806B (es) 2025-03-11
IL262387A (en) 2018-12-31
CA3022482C (en) 2024-06-11
US20190365701A1 (en) 2019-12-05
WO2017191130A4 (en) 2018-03-01
EP3452485B1 (en) 2020-09-09
US10912755B2 (en) 2021-02-09
BR112018072545B1 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
IL262387B (en) Arginase inhibitors and treatment applications thereof
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL258970A (en) Bivalent bromodomain inhibitors and their uses
IL280863A (en) Autotaxin inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
IL263949A (en) Complement inhibitors and their uses
SI3532459T1 (sl) Zaviralci LSD1 in njihove medicinske uporabe
SMT202400438T1 (it) Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL254916B (en) Inhibitors and their uses
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
ZA201803212B (en) Gelatinase inhibitors and use thereof
ZA201808008B (en) Arginase inhibitors and their therapeutic applications
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses